n = 1 Exclusion min n = 2 patients also had Coagulation disorders or liver failure bone metastases Objectives Report of institutional experience and outcomes Included primary cancer Liang et al () Case series n = 13 Inclusion MTA Outcomes patients but provided Taiwan Level IV all CRC metastases Unresectable tumours or refused Open = 10 Ablation success, recurrence, separate results surgery complications Quality: poor Male/female: 7/6 Laparoscopic = 3 Tumours 4–7 cm diameter Statistical analyses Mean age: 69.2 ± 9.08 (MedWaves AveCure MWA y Exclusion system, San Diego, CA, None undertaken USA) Mean tumour size None described Duration of follow-up (cm): 5.31 902–928 MHz, 10–32 W Objectives Mean 16.5 months No of sessions, mean ± SD: Evaluate safety and efficacy of 2.23 ± 0.73 novel MTA system in cancers exceeding 4 cm Time, mean ± SD: 1823 ± 641.8 s Martin et al () Case series N = 20, 67 tumours Inclusion Open or laparoscopic MTA Outcomes 9/20 patients underwent (Vivant Medical microwave additional procedures USA Level IV HCC = 5 Liver tumours amenable to Ablation success, recurrence, system, Mountain View, such as partial complete ablation or combination of complications Quality: moderate Metastases from California, USA) hepatectomy, colectomy resection and ablation Statistical analysis CRC = 10 and gastrectomy 915 MHz 18+ years None undertaken Carcinoid = 2 Mean ablation time 10 min Exclusion Duration of follow-up Ovarian = 1 (5–40 min) Metastases amenable to resection Median 19 months (range 5–23 Breast = 1 Median operative time 106 alone months) Gastric = 1 min (47–249 min) Tumour >7 cm Male/female: 13/7 Objectives Median age (range): To evaluate safety, operative time, 65 (46–83) y rate of complete ablation and local recurrence Li et al () Case series N = 49; 61 lesions Inclusion Percutaneous MTA Outcomes Following up outcomes 2000, Kangyou Medical, of MTA in pop 2 was not China Level IV Lesions from: Unresectable tumour or resection Complete ablation, local
n = 1 n = 2 patients also had bone metastases Exclusion Coagulation disorders or liver failure Objectives Report of institutional experience and outcomes min Liang et al () Taiwan Case series Level IV Quality: poor n = 13 all CRC metastases Male/female: 7/6 Mean age: 69.2 ± 9.08 y Mean tumour size (cm): 5.31 Inclusion Unresectable tumours or refused surgery Tumours 4–7 cm diameter Exclusion None described Objectives Evaluate safety and efficacy of novel MTA system in cancers exceeding 4 cm MTA Open = 10 Laparoscopic = 3 (MedWaves AveCure MWA system, San Diego, CA, USA) 902–928 MHz, 10–32 W No of sessions, mean ± SD: 2.23 ± 0.73 Time, mean ± SD: 1823 ± 641.8 s Outcomes Ablation success, recurrence, complications Statistical analyses None undertaken Duration of follow-up Mean 16.5 months Included primary cancer patients but provided separate results Martin et al () USA Case series Level IV Quality: moderate N = 20, 67 tumours HCC = 5 Metastases from CRC = 10 Carcinoid = 2 Ovarian = 1 Breast = 1 Gastric = 1 Male/female: 13/7 Median age (range): 65 (46–83) y Inclusion Liver tumours amenable to complete ablation or combination of resection and ablation 18+ years Exclusion Metastases amenable to resection alone Tumour >7 cm Objectives To evaluate safety, operative time, rate of complete ablation and local recurrence Open or laparoscopic MTA (Vivant Medical microwave system, Mountain View, California, USA) 915 MHz Mean ablation time 10 min (5–40 min) Median operative time 106 min (47–249 min) Outcomes Ablation success, recurrence, complications Statistical analysis None undertaken Duration of follow-up Median 19 months (range 5–23 months) 9/20 patients underwent additional procedures such as partial hepatectomy, colectomy and gastrectomy Li et al () China Case series Level IV N = 49; 61 lesions Lesions from: Inclusion Unresectable tumour or resection Percutaneous MTA Kangyou Medical, Outcomes Complete ablation, local Following up outcomes of MTA in pop 2 was not 2000,